ALK and T-cell non-Hodgkin lymphoma: The findings presented herein are expected to further advance current understanding of the pathobiology of NPM-ALK+ T-cell lymphoma and may contribute to the development of novel therapeutic approaches to efficiently eradicate this aggressive cancer.